Cognition Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Cognition Therapeutics, Inc. (CGTX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of 2.80% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2025-03-20
- Cognition Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was 2.80%, a 37.78% decline from fiscal 2023.
- Cognition Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was 4.50%.
- Cognition Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -15.10%, a 234.82% decline from fiscal 2021.
- Cognition Therapeutics, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 11.20%, a 4.67% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month |
|---|---|
| 2024-12-31 | 2.80% 10-K · filed 2025-03-20 |
| 2023-12-31 | 4.50% 10-K · filed 2025-03-20 |
| 2022-12-31 | -15.10% 10-K · filed 2024-03-26 |
| 2021-12-31 | 11.20% 10-K · filed 2023-03-23 |
| 2020-12-31 | 10.70% 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |